Phase: Phase III
Class: Cyclin-dependent kinase (CDK) 4&6 inhibitor
2020 sales: $2.95 billion
Net present value: $7.9 billion
After going through the biggest R&D reorganization in industry history, Pfizer ($PFE) was left with a rather thin pipeline for a Big Pharma player. Palbociclib is one of a handful of standout programs at the company. But when it broadcast the news last May that it will go ahead and file for an approval for palbociclib, a closely-watched CDK 4/6 inhibitor, on Phase II data, the market essentially shrugged. Pfizer CEO Ian Read was being publicly chided at the time for pushing a megamerger with AstraZeneca ($AZN) long after Pfizer had provided ample evidence that megamergers typically flop. And the news couldn't overcome some miserable Q1 numbers that illustrated just how badly the company needs to do something effective. As it stands, some of the top analysts in the biz give palbociclib a solid shot at an accelerated approval. But even if it does come in around $3 billion--a rosy forecast--serious competition is coming up from behind.
Why did Pfizer's big fiesta for palbociclib fizzle?
Pfizer's flagship palbociclib stymies cancer progression but falls short on survival
All eyes on Pfizer as palbociclib prepares to take the stage